American Vanguard (AVD) 10-Q 31 Jul 15 2015 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2015	Jul. 23, 2015
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q2
Trading Symbol	AVD
Entity Registrant Name	AMERICAN VANGUARD CORP
Entity Central Index Key	5,981
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		29,201,607

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Net sales	$ 66,523	$ 68,313	$ 133,088	$ 149,408
Cost of sales	41,402	42,253	83,317	94,443
Gross profit	25,121	26,060	49,771	54,965
Operating expenses	23,922	25,337	48,266	50,536
Operating income	1,199	723	1,505	4,429
Interest expense	710	857	1,390	1,488
Interest capitalized	(48)	(13)	(87)	(31)
Income (loss) before provision for income taxes and loss on equity investment	537	(121)	202	2,972
Income taxes (benefit) expense	(393)	(160)	(685)	856
Income before loss on equity investment	930	39	887	2,116
Less net loss from equity method investment	(191)	(68)	(191)	(140)
Net income (loss)	739	(29)	696	1,976
Add back net loss attributable to non-controlling interest	42	174	136	328
Net income attributable to American Vanguard	781	145	832	2,304
Change in fair value of interest rate swaps		145		281
Foreign currency translation adjustment	(323)	92	(571)	143
Comprehensive income	$ 458	$ 382	$ 261	$ 2,728
Earnings per common share-basic	$ 0.03	$ 0.01	$ 0.03	$ 0.08
Earnings per common share-assuming dilution	$ 0.03	$ 0.01	$ 0.03	$ 0.08
Weighted average shares outstanding-basic	28,676	28,408	28,602	28,404
Weighted average shares outstanding-assuming dilution	29,202	28,795	29,103	28,877

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 5,089	$ 4,885
Receivables:
Trade, net of allowance for doubtful accounts of $123 and $166, respectively	74,698	86,027
Other	4,750	2,396
Total receivables	79,448	88,423
Inventories	165,234	165,631
Prepaid expenses	13,133	13,415
Income taxes receivable	6,849	5,964
Deferred income tax assets	8,731	8,731
Total current assets	278,484	287,049
Property, plant and equipment, net	48,975	50,026
Intangible assets, net of applicable amortization	133,129	100,211
Other assets	32,415	35,035
Total assets	493,003	472,321
Current liabilities:
Current installments of other notes payable	10,072	71
Current installments of other liabilities	2,098	1,357
Accounts payable	20,019	20,411
Deferred revenue	4,509	898
Accrued program costs	69,603	52,546
Accrued expenses and other payables	5,052	5,962
Total current liabilities	111,353	81,245
Long-term debt and other notes payable, excluding current installments	87,614	98,605
Other liabilities, excluding current installments	2,994	3,309
Deferred income tax liabilities	28,159	28,159
Total liabilities	$ 230,120	$ 211,318
Commitments and contingent liabilities
Stockholders' equity:
Preferred stock, $.10 par value per share; authorized 400,000 shares; none issued
Common stock, $.10 par value per share; authorized 40,000,000 shares; issued 31,617,282 shares at June 30, 2015 and 31,550,477 shares at December 31, 2014	$ 3,162	$ 3,156
Additional paid-in capital	67,714	66,232
Accumulated other comprehensive loss	(2,541)	(1,970)
Retained earnings	202,748	202,488
Total stockholders' equity including treasury stock	271,083	269,906
Less treasury stock, at cost, 2,450,634 shares at June 30, 2015 and December 31, 2014	(8,269)	(8,269)
American Vanguard Corporation stockholders' equity	262,814	261,637
Non-controlling interest	69	(634)
Total stockholders' equity	262,883	261,003
Total liabilities and stockholders' equity	$ 493,003	$ 472,321

CONDENSED CONSOLIDATED BALANCE4

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Allowance for doubtful accounts	$ 123	$ 166
Preferred stock, par value per share	$ 0.10	$ 0.10
Preferred stock, shares authorized	400,000	400,000
Preferred stock, shares issued	0	0
Common stock, par value per share	$ 0.10	$ 0.10
Common stock, shares authorized	40,000,000	40,000,000
Common stock, shares issued	31,617,282	31,550,477
Treasury stock, shares	2,450,634	2,450,634

CONDENSED CONSOLIDATED STATEME5

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Treasury Stock	AVD Total	Non- Controlling Interest
Balance (in shares) at Dec. 31, 2014	31,550,477	31,550,477				2,450,634
Balance at Dec. 31, 2014	$ 261,003	$ 3,156	$ 66,232	$ 202,488	$ (1,970)	$ (8,269)	$ 261,637	$ (634)
Stocks issued under ESPP (in shares)		24,144
Stocks issued under ESPP	280	$ 2	278				280
Cash dividends on common stock ($0.02 per share)	(572)			(572)			(572)
Foreign currency translation adjustment, net	(248)				(248)		(248)
Stock based compensation	1,427		1,427				1,427
Stock options exercised and grants and vesting of restricted stock units (in shares)		(11,943)
Stock options exercised and grants and vesting of restricted stock units	(1,245)	$ (1)	(1,244)				(1,245)
Excess tax benefits from share based payment arrangements	1		1				1
Net (loss) income	(43)			51			51	(94)
Balance (in shares) at Mar. 31, 2015		31,562,678				2,450,634
Balance at Mar. 31, 2015	$ 260,603	$ 3,157	66,694	201,967	(2,218)	$ (8,269)	261,331	(728)
Balance (in shares) at Dec. 31, 2014	31,550,477	31,550,477				2,450,634
Balance at Dec. 31, 2014	$ 261,003	$ 3,156	66,232	202,488	(1,970)	$ (8,269)	261,637	(634)
Foreign currency translation adjustment, net	(571)
Net (loss) income	$ 696
Balance (in shares) at Jun. 30, 2015	31,617,282	31,617,282				2,450,634
Balance at Jun. 30, 2015	$ 262,883	$ 3,162	67,714	202,748	(2,541)	$ (8,269)	262,814	69
Balance (in shares) at Mar. 31, 2015		31,562,678				2,450,634
Balance at Mar. 31, 2015	260,603	$ 3,157	66,694	201,967	(2,218)	$ (8,269)	261,331	(728)
Stocks issued under ESPP	(12)		(12)				(12)
Foreign currency translation adjustment, net	(323)				(323)		(323)
Stock based compensation	1,058		1,058				1,058
Stock options exercised and grants and vesting of restricted stock units (in shares)		54,604
Stock options exercised and grants and vesting of restricted stock units	937	$ 5	932				937
Adjustment and purchase of non-controlling interest	(125)		(964)				(964)	839
Excess tax benefits from share based payment arrangements	6		6				6
Net (loss) income	$ 739			781			781	(42)
Balance (in shares) at Jun. 30, 2015	31,617,282	31,617,282				2,450,634
Balance at Jun. 30, 2015	$ 262,883	$ 3,162	$ 67,714	$ 202,748	$ (2,541)	$ (8,269)	$ 262,814	$ 69

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)	3 Months Ended
	Mar. 31, 2015$ / shares
Cash dividends on common stock, per share	$ 0.02

CONDENSED CONSOLIDATED STATEME7

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Cash flows from operating activities:
Net income	$ 696	$ 1,976
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation and amortization of fixed and intangible assets	7,864	7,996
Amortization of other long term assets	2,734	3,027
Amortization of discounted liabilities	154	175
Stock-based compensation	2,485	1,806
Tax benefit from exercise of stock options	(7)	(262)
Operating loss from equity method investment	191	396
Gain from dilution of equity method investment		(256)
Changes in assets and liabilities associated with operations:
Decrease (increase) in net receivables	8,975	(1,025)
Decrease (increase) in inventories	397	(35,410)
Decrease (increase) in prepaid expenses and other assets	143	(5,049)
(Increase) decrease in income tax receivable/payable, net	(878)	120
Decrease in accounts payable	(392)	(16,521)
Increase (decrease) in deferred revenue	3,611	(2,276)
Increase in other payables and accrued expenses	17,851	16,264
Net cash provided by (used in) operating activities	43,824	(29,039)
Cash flows from investing activities:
Capital expenditures	(3,480)	(3,954)
Investment	(125)
Acquisitions of product lines and other intangibles assets	(36,435)
Net cash used in investing activities	(40,040)	(3,954)
Cash flows from financing activities:
Net (payments) borrowings under line of credit agreement	(11,120)	34,430
Increase in other notes payable	10,000
Payments on other long-term liabilities	(899)	(1,109)
Tax benefit from exercise of stock options	7	262
Repurchases of common stock		(1,531)
Payment of cash dividends	(1,141)	(2,836)
Net (payments) proceeds from the issuance of common stock (sale of stock under ESPP and exercise of stock options)	(40)	1,196
Net cash (used in) provided by financing activities	(3,193)	30,412
Net increase (decrease) in cash and cash equivalents	591	(2,581)
Cash and cash equivalents at beginning of period	4,885	6,680
Effect of exchange rate changes on cash	(387)	90
Cash and cash equivalents at end of period	$ 5,089	$ 4,189

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2015
Summary of Significant Accounting Policies	1. The accompanying unaudited condensed consolidated financial statements of American Vanguard Corporation and Subsidiaries (“AVD”) have been prepared in accordance with generally accepted accounting principles in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation, have been included. Operating results for the six months ended June 30, 2015 are not necessarily indicative of the results that may be expected for the year ending December 31, 2015. For further information, refer to the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014.

Property, plant and equipment

Property, plant and equipment	6 Months Ended
	Jun. 30, 2015
Property, plant and equipment	2. Property, plant and equipment at June 30, 2015 and December 31, 2014 consists of the following: June 30, December 31, Land $ 2,458 $ 2,458 Buildings and improvements 14,388 14,380 Machinery and equipment 108,904 107,899 Office furniture, fixtures and equipment 4,718 4,698 Automotive equipment 492 374 Construction in progress 5,591 3,432 136,551 133,241 Less accumulated depreciation (87,576 ) (83,215 ) $ 48,975 $ 50,026 During the six months ended June 30, 2015, the Company eliminated from assets and accumulated depreciation of $231 of fully depreciated assets. Substantially all of the Company’s assets are pledged as collateral with its banks.

Inventories

Inventories	6 Months Ended
	Jun. 30, 2015
Inventories	3. Inventories are stated at the lower of cost or market. Cost is determined using the first-in, first-out method. The components of inventories consist of the following: June 30, December 31, Finished products $ 140,142 $ 142,853 Raw materials 25,092 22,778 $ 165,234 $ 165,631

Segment Reporting

Segment Reporting	6 Months Ended
	Jun. 30, 2015
Segment Reporting	4. Based on similar economic and operational characteristics, the Company’s business is aggregated into one reportable segment. Selective enterprise information is as follows: Three Months Ended Six Months Ended 2015 2014 2015 2014 Net sales: Insecticides $ 27,586 $ 34,524 $ 61,945 $ 80,961 Herbicides/soil fumigants/fungicides 17,451 13,926 39,291 36,857 Other, including plant growth regulators 12,755 8,929 16,077 12,736 57,792 57,379 117,313 130,554 Non-crop 8,731 10,934 15,775 18,854 $ 66,523 $ 68,313 $ 133,088 $ 149,408 Three Months Ended Six Months Ended 2015 2014 2015 2014 Net sales: US $ 43,842 $ 50,094 $ 93,064 $ 108,050 International 22,681 18,219 40,024 41,358 $ 66,523 $ 68,313 $ 133,088 $ 149,408

Accrued Program Costs

Accrued Program Costs	6 Months Ended
	Jun. 30, 2015
Accrued Program Costs	5. Accrued Program Costs

Cash Dividends

Cash Dividends	6 Months Ended
	Jun. 30, 2015
Cash Dividends	6. The Company declared the following cash dividends in the period covered by this Form 10-Q: Declaration Date Distribution Date Record Date Dividend Per Share Total Paid March 16, 2015 April 17, 2015 April 3, 2015 $0.02 $572

Earnings Per Share

Earnings Per Share	6 Months Ended
	Jun. 30, 2015
Earnings Per Share	7. ASC 260 Earnings Per Share (“EPS” The components of basic and diluted earnings per share were as follows: Three Months Ended Six Months Ended 2015 2014 2015 2014 Numerator: Net income attributable to AVD $ 781 $ 145 $ 832 $ 2,304 Denominator: Weighted averages shares outstanding-basic 28,676 28,408 28,602 28,404 Dilutive effect of stock options and grants 526 387 501 473 29,202 28,795 29,103 28,877 For the three months and six months ended June 30, 2015, no stock options were excluded from the computation of diluted earnings per share. The Company excluded 2,385 stock options from the computation of diluted earnings per share for the three months ended June 30, 2014 and 4,591 stock options from the computation of diluted earnings per share for the six months ended June 30, 2014, because they were anti-dilutive.

Indebtedness

Indebtedness	6 Months Ended
	Jun. 30, 2015
Indebtedness	8. The Company has a revolving line of credit and various notes payable that together constitute the short-term and long-term loan balances shown in the condensed consolidated balance sheets at June 30, 2015 and December 31, 2014. These are summarized in the following table: Indebtedness June 30, 2015 December 31, 2014 $000’s Long- Short- Total Long- Short- Total Revolving line of credit $ 88,400 $ — $ 88,400 $ 99,400 $ — $ 99,400 Deferred loan fees (804 ) — (804 ) (850 ) — (850 ) Notes payable 18 10,072 10,090 55 71 126 Total indebtedness $ 87,614 $ 10,072 $ 97,686 $ 98,605 $ 71 $ 98,676 On June 17, 2013, AMVAC Chemical Corporation (“AMVAC”), the Company’s principal operating subsidiary, as borrower, and affiliates (including the Company), as guarantors and/or borrowers, entered into a Second Amended and Restated Credit Agreement (the “New Credit Agreement”) with a group of commercial lenders led by Bank of the West (AMVAC’s primary bank) as agent, swing line lender and L/C issuer. The new facility also includes both AMVAC C.V. and AMVAC Netherlands B.V. (both Dutch subsidiaries) as borrowers. The New Credit Agreement supersedes the Amended and Restated Credit Agreement (“First Amendment”) dated as of January 10, 2011. The New Credit Agreement is a senior secured lending facility with a five year term and consists of a revolving line of credit with a maximum limit of $200 million and an accordion feature with a maximum limit of $100 million. The actual borrowing capacity under this facility depends upon its compliance with the key covenants described below. In connection with AMVAC’s entering into the New Credit Agreement, all outstanding indebtedness under the First Amendment was rolled over into the New Credit Agreement, including the conversion of term loans into revolving debt. On July 18, 2014, AMVAC, as borrower, and affiliates (including the Company), as guarantors and/or borrowers, entered into a First Amendment to Second Amended and Restated Credit Agreement (the “First Amendment”) with a group of commercial lenders led by Bank of the West (AMVAC’s primary bank) as agent, swing line lender and L/C issuer. Under the First Amendment, the Consolidated Funded Debt Ratio was increased for the third and fourth quarters of 2014 and the first quarter of 2015, and, further, borrowers are permitted to pay cash dividends to stockholders during the first and second quarters of 2015 notwithstanding prior net income levels. On April 28, 2015, AMVAC and affiliates (including the Company), as guarantors and/or borrowers, entered into a Second Amendment to Second Amended and Restated Credit Agreement (the “Second Amendment”) with a group of commercial lenders led by Bank of the West (AMVAC’s primary bank) as agent, swing line lender and L/C issuer. Under the Second Amendment, the Consolidated Funded Debt Ratio was increased for the second, third and fourth quarters of 2015. The Company has three key covenants to its senior, secured credit facility with its banking syndicate. The covenants are as follows: (1) the Company must maintain its borrowings below a certain consolidated funded debt ratio (taking into account the Company’s twelve month trailing EBITDA), (2) the Company has a limitation on its annual spending on the acquisition of fixed asset capital additions, and (3) the Company must maintain a certain consolidated fixed charge coverage ratio. As of June 30, 2015 the Company met all covenants in that credit facility. At June 30, 2015, based on its performance against the most restrictive covenants listed above, the Company had the capacity to increase its borrowings by up to $27,101 under the credit facility agreement. This compares to an available borrowing capacity of $64,057 as of June 30, 2014. This decrease in borrowing availability arises from reduced financial performance (as measured in EBITDA) for the trailing twelve month period and increased borrowings associated with product line acquisitions. During the three month and six month periods ended June 30, 2014 (and throughout the balance of 2014, terminating on December 31, 2014), the Company had in place one interest rate swap contract. While in place, the interest rate swap contract was accounted for under FASB ASC 815 as a cash flow hedge. The effective portion of the gains or losses on the interest rate swap were reported as a component of other comprehensive income and reclassified into earnings in the same period or periods during which the hedged transactions affected earnings. As a result of the termination of the swap contract, there were no gains or losses in other comprehensive income (“OCI”) related to interest rate swap contracts that were expected to be reclassified to earnings in the coming 12 months. The following tables illustrate the impact of derivatives on the Company’s statements of operations and comprehensive income for the three months and six months ended June 30, 2015 and 2014. The Effect of Derivative Instruments on the Statement of Financial Performance For the three months ended June 30, 2015 and 2014 Amount of Gain or Location of Gain or Amount of Gain or (Loss) Location of Gain or Amount of Gain or Derivatives in ASC 815 Cash Flow Hedging Relationships 2015 2014 OCI into Income 2015 2014 Income on Derivative 2015 2014 Interest rate contracts $ — $ (8 ) Interest Expense $ — $ (153 ) Interest Expense $ — $ — Total $ — $ (8 ) $ — $ (153 ) $ — $ — For the six months ended June 30, 2015 and 2014 Amount of Gain or Location of Gain or Amount of Gain or (Loss) Location of Gain or Amount of Gain or Derivatives in ASC 815 Cash Flow Hedging Relationships 2015 2014 OCI into Income 2015 2014 Income on Derivative 2015 2014 Interest rate contracts $ — $ (31 ) Interest Expense $ — $ (312 ) Interest Expense $ — $ — Total $ — $ (31 ) $ — $ (312 ) $ — $ —

Reclassification

Reclassification	6 Months Ended
	Jun. 30, 2015
Reclassification	9. Reclassification—Certain items may have been reclassified in the prior period condensed consolidated financial statements to conform with the June 30, 2015 presentation.

Comprehensive (Loss) Income

Comprehensive (Loss) Income	6 Months Ended
	Jun. 30, 2015
Comprehensive (Loss) Income	10. Total comprehensive income includes, in addition to net income, changes in equity that are excluded from the condensed consolidated statements of operations and are recorded directly into a separate section of stockholders’ equity on the condensed consolidated balance sheets. For the three month and six month periods ended June 30, 2015, total comprehensive income consisted of net income attributable to American Vanguard and foreign currency translation adjustments.

Stock Based Compensation

Stock Based Compensation	6 Months Ended
	Jun. 30, 2015
Stock Based Compensation	11. Stock Based Compensation—The Company accounts for stock-based awards to employees and directors in accordance with FASB ASC 718, “ Share-Based Payment The below tables illustrate the Company’s stock based compensation, unamortized stock-based compensation, and remaining weighted average period for the three months and six months ended June 30, 2015 and 2014. Stock-Based Stock-Based Unamortized Remaining June 30, 2015 Incentive Stock Options $ 116 $ 231 $ 1,204 2.5 Restricted Stock 790 1,962 3,521 1.5 Performance Based Restricted Stock 107 205 811 2.0 Performance Based Options 45 87 454 2.5 Total $ 1,058 $ 2,485 $ 5,990 June 30, 2014 Incentive Stock Options $ 10 $ 21 $ — — Restricted Stock 985 1,819 7,153 2.1 Performance Based Restricted Stock 43 (34 ) 1,559 2.6 Total $ 1,038 $ 1,806 $ 8,712 Stock Options—During the six months ended June 30, 2015, the Company did not grant any employees options to acquire shares of common stock. Option activity within each plan is as follows: Incentive Weighted Average Exercisable Balance outstanding, December 31, 2014 724,904 $ 9.22 $ 7.82 Options exercised, $7.50 (16,650 ) 7.50 Options forfeited, $11.49 and $13.24 (10,400 ) 11.49 Balance outstanding, March 31, 2015 697,854 $ 9.21 $ 7.71 Options exercised, $7.50 (34,800 ) 7.50 Options forfeited, $11.49 (2,481 ) 11.49 Balance outstanding, June 30, 2015 660,573 $ 9.29 $ 7.72 Information relating to stock options at June 30, 2015 summarized by exercise price is as follows: Outstanding Weighted Average Exercisable Weighted Exercise Price Per Share Shares Remaining Exercise Shares Exercise Incentive Stock Option Plan: $7.50 369,750 64 $ 7.50 369,750 $ 7.50 $11.32—$14.75 290,823 111 $ 11.56 16,679 $ 12.69 660,573 $ 9.29 386,429 $ 7.72 The weighted average exercise prices for options granted and exercisable and the weighted average remaining contractual life for options outstanding as of June 30, 2015 was as follows: Number Weighted Weighted Intrinsic As of June 30, 2015: Incentive Stock Option Plans: Outstanding 660,573 $ 9.29 85 $ 2,987 Expected to Vest 650,455 $ 9.25 84 $ 2,964 Exercisable 386,429 $ 7.72 64 $ 2,354 During the three months ended June 30, 2015 and 2014, the Company recognized stock-based compensation related to stock options of $116 and $10, respectively. During the six months ended June 30, 2015 and 2014, the Company recognized stock-based compensation related to stock options of $231 and $21, respectively. As of June 30, 2015, the Company had approximately $1,204 of unamortized stock-based compensation related to unvested stock options outstanding. This amount will be recognized over the weighted-average period of 2.5 years. This projected expense will change if any stock options are granted or cancelled prior to the respective reporting periods or if there are any changes required to be made for estimated forfeitures. Restricted Shares — Number Weighted Nonvested shares at December 31, 2014 560,842 $ 21.44 Granted 30,000 11.42 Vested (192,266 ) 20.47 Forfeited (422 ) 14.92 Nonvested shares at March 31, 2015 398,154 $ 21.17 Granted 21,005 14.28 Vested (28,505 ) 13.53 Forfeited (1,201 ) 14.92 Nonvested shares at June 30, 2015 389,453 $ 21.37 Restricted stock grants — During the six months ended June 30, 2015, the Company granted a total of 51,005 shares of common stock. Of these, 21,005 shares vest immediately, 7,500 shares will vest after 90 days and the balance will cliff vest after three years of service. The shares granted in 2015 were average fair valued at $12.60 per share. The fair value was determined by using the publicly traded share price as of the date of grant. The Company is recognizing as expense the value of restricted shares over the required service period. During the six months ended June 30, 2014, the Company granted a total of 240,724 shares of common stock. Of these, 23,478 shares vest immediately, and the balance will cliff vest after three years of service. The shares granted in 2014 were average fair valued at $14.81 per share. The fair value was determined by using the publicly traded share price as of the date of grant. The Company is recognizing as expense the value of restricted shares over the required service period. During the three months ended June 30, 2015 and 2014, the Company recognized stock-based compensation related to restricted shares of $790 and $985, respectively. During the six months ended June 30, 2015 and 2014, the Company recognized stock-based compensation related to restricted shares of $1,962 and $1,819, respectively. As of June 30, 2015, the Company had approximately $3,521 of unamortized stock-based compensation related to unvested restricted shares. This amount will be recognized over the weighted-average period of 1.5 years. This projected expense will change if any restricted shares are granted or cancelled prior to the respective reporting periods or if there are any changes required to be made for estimated forfeitures. Performance Based Shares — Number Weighted Nonvested shares at December 31, 2014 103,907 $ 17.81 Granted 7,500 10.96 Vested — — Forfeited — — Nonvested shares at March 31, 2015 111,407 $ 17.35 Granted — — Vested — — Forfeited — — Nonvested shares at June 30, 2015 111,407 $ 17.35 Performance Based Shares — During the six months ended June 30, 2015, the Company granted a total of 7,500 performance based shares that will cliff vest on January 5, 2018, provided that the recipient is continuously employed by the Company during the vesting period. Eighty percent of these performance based shares are based upon financial performance of the Company, specifically, an earnings before income tax (“EBIT”) goal weighted at 50% and a net sales goal weighted at 30% for the period commencing January 1, 2015 and ending December 31, 2017. The remaining 20% of performance based shares are based upon AVD stock price appreciation over the same performance measurement period. The EBIT and net sales goals measure the relative growth of the Company’s EBIT and net sales for the performance measurement period, as compared to the median growth of EBIT and net sales for an identified peer group. The stockholder return goal measures the relative growth of the fair market value of the Company’s stock price over the performance measurement period, as compared to that of the Russell 2000 Index and the median fair market value of the common stock of the comparator companies, identified in the Company’s 2015 Proxy Statement. All parts of these awards vest in three years, but are subject to reduction to a minimum (or even zero) for meeting less than the targeted performance and to increase to a maximum of 200% for meeting in excess of the targeted performance. The Company did not grant any performance based shares during the comparable period last year. As of June 30, 2015, performance based shares related to net income and net sales have an average fair value of $11.42 per share. The fair value was determined by using the publicly traded share price as of the date of grant. The performance based shares related to the Company’s stock price have an average fair value of $9.13 per share. The fair value was determined by using the Monte Carlo valuation method. For awards with performance conditions, the Company recognizes share-based compensation cost on a straight-line basis for each performance criteria over the implied service period when the Company believes it is probable that the performance targets, as defined in the agreements, will be achieved. During the three months ended June 30, 2015 and 2014, the Company recognized stock-based compensation related to performance based shares of $107 and $43, respectively. During the six months ended June 30, 2015, the Company recognized stock-based compensation related to performance based shares of $205. During the six months ended June 30, 2014, the Company recognized a reduction in stock-based compensation related to performance based shares of $34. As of June 30, 2015, the Company had approximately $811 of unamortized stock-based compensation related to unvested performance based shares. This amount will be recognized over the weighted-average period of 2.0 years. This projected expense will change if any performance based shares are granted or cancelled prior to the respective reporting periods or if there are any changes required to be made for estimated forfeitures. Performance Incentive Stock Options—During the six months ended June 30, 2015 and 2014, the Company did not grant any employees performance incentive stock options to acquire shares of common stock. Performance option activity is as follows: Incentive Weighted Average Exercisable Balance outstanding, December 31, 2014 107,689 $ 11.49 $ — Balance outstanding, June 30, 2015 107,689 $ 11.49 $ — Information relating to outstanding stock options at June 30, 2015 summarized by exercise price is as follows: Outstanding Weighted Average Exercisable Weighted Exercise Price Per Share Shares Remaining Exercise Shares Exercise Performance Incentive Stock Option Plan: $11.49 107,689 30 $ 11.49 — $ — 107,689 $ 11.49 — $ — The weighted average exercise prices for options granted and exercisable and the weighted average remaining contractual life for options outstanding as of June 30, 2015 are as follows: Number Weighted Weighted Intrinsic As of June 30, 2015: Incentive Stock Option Plans: Outstanding 107,689 $ 11.49 30 $ 199 Expected to Vest 107,689 $ 11.49 30 $ 199 Exercisable — $ — — $ — During the three months ended June 30, 2015 the Company recognized stock-based compensation related to performance stock options of $45. There were no performance incentive stock options issued by the Company prior to those issued during the quarter ended December 31, 2014. During the six months ended June 30, 2015 the Company recognized stock-based compensation related to performance stock options of $87. There were no performance incentive stock options issued by the Company prior to those issued during the quarter ended December 31, 2014. As of June 30, 2015, the Company had approximately $454 of unamortized stock-based compensation related to unvested performance incentive stock options outstanding. This amount will be recognized over the weighted-average period of 2.5 years. This projected expense will change if any performance incentive stock options are granted or cancelled prior to the respective reporting periods or if there are any changes required to be made for estimated forfeitures.

Legal Proceedings

Legal Proceedings	6 Months Ended
	Jun. 30, 2015
Legal Proceedings	12. Legal proceedings—During the reporting period, there have been no material developments in the legal proceedings that were reported in the Company’s Form 10-K for the period ended December 31, 2014, other than as discussed below: Sanchez v. Agro Logistics Sanchez v. Agro Logistic Systems, Inc. et al Galvan v. AMVAC Graciela Galvan v. AMVAC Chemical Corp. USEPA RCRA Matter USEPA TSCA Matter Schiemer Farms Matter

Recently Issued Accounting Guid

Recently Issued Accounting Guidance	6 Months Ended
	Jun. 30, 2015
Recently Issued Accounting Guidance	13. Recently Issued Accounting Guidance—In April 2015, The Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2015-03, Interest – Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. In August 2014, FASB issued ASU 2014-15, Presentation of Financial Statements – Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. In June 2014, The Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-12, Compensation—Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period, a consensus of the FASB Emerging Issues Task Force In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers

Fair Value of Financial Instrum

Fair Value of Financial Instruments	6 Months Ended
	Jun. 30, 2015
Fair Value of Financial Instruments	14. Fair Value of Financial Instruments—The carrying values of cash, receivables and accounts payable approximate their fair values because of the short maturity of these instruments. The fair value of the Company’s long-term debt and note payable to bank is estimated based on the quoted market prices for the same or similar issues or on the current rates offered to the Company for debt of the same remaining maturities. Such fair value approximates the respective carrying values of the Company’s long-term debt and note payable to bank.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income ("AOCI")	6 Months Ended
	Jun. 30, 2015
Accumulated Other Comprehensive Income ("AOCI")	15. Accumulated Other Comprehensive Income (“AOCI”) — The following table lists the beginning balance, annual activity and ending balance of accumulated other comprehensive loss, which consists of foreign currency translation adjustments: Balance, December 31, 2014 $ (1,970 ) Other comprehensive loss (248 ) Balance, March 31, 2015 $ (2,218 ) Other comprehensive loss (323 ) Balance, June 30, 2015 $ (2,541 )

Equity Investment

Equity Investment	6 Months Ended
	Jun. 30, 2015
Equity Investment	16. On March 25, 2013, the Company made a $3,687 equity investment in TyraTech Inc. (“TyraTech”), a Delaware corporation that specializes in developing, marketing and selling pesticide products containing essential oils and other natural ingredients, to acquire an ownership position of approximately 29.27%. In February 2014, TyraTech issued 37,391,763 shares and raised approximately £1,870 ($3,100). Due to the share issuance, the Company recognized a $256 gain from the dilution of the Company’s ownership position. As of June 30, 2015, the Company’s ownership position in TyraTech was approximately 21.18%. The Company utilizes the equity method of accounting with respect to this investment. As a result, our net income includes losses from equity method investments, which represents our proportionate share of TyraTech’s estimated net losses for the current accounting period. For the six months ended June 30, 2015, the Company recognized a loss of $191 as a result of the Company’s ownership position in TyraTech. The Company’s investment in TyraTech is included in other assets on the condensed consolidated balance sheet. At June 30, 2015, the carrying value of the Company’s investment in TyraTech was $2,981 and the quoted market value of its shareholding was $4,148 based on the London Stock Exchange, Alternative Investment Market (“AIM”).

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2015
Income Taxes	17. Income Taxes – Income tax benefit was $685 for the six months ended June 30, 2015 as compared to an income tax expense of $856 for the six months ended June 30, 2014. The effective tax rate was a benefit of (339.1%) in 2015 and an expense of 27.0% in 2014. Income tax benefit was $393 for the three months ended June 30, 2015 and $160 for the three months ended June 30, 2014. The effective tax rate for the six months ended June 30, 2015 is based on the financial statements for the six months ended June 30, 2015. It became increasingly difficult to estimate a reliable annual effective tax rate for the 2015 financial year because of the uncertainty in forecasting taxable income or loss for the remainder of the year for each of our domestic and international operations. Significant changes in our estimated annual effective tax rate could result from changes in forecasts or actual results for either our domestic or international operations. Since an estimated annual effective tax rate under these circumstances would not provide a meaningful estimate, an actual year-to-date effective tax rate is the best estimate of the annual tax rate.

Product Acquisitions

Product Acquisitions	6 Months Ended
	Jun. 30, 2015
Product Acquisitions	18. Product Acquisitions – On April 6, 2015, the Company completed the acquisition of a nematicide product line, Nemacur, in Europe from Adama Agricultural Solutions Ltd. Further on April 29, 2015, the Company completed the acquisition of the global herbicide product line, Hyvar/Krovar from DuPont. These product acquisitions were immaterial to the Company’s condensed consolidated financial statements.

Property, plant and equipment (

Property, plant and equipment (Tables)	6 Months Ended
	Jun. 30, 2015
Summary of Property, Plant and Equipment	Property, plant and equipment at June 30, 2015 and December 31, 2014 consists of the following: June 30, December 31, Land $ 2,458 $ 2,458 Buildings and improvements 14,388 14,380 Machinery and equipment 108,904 107,899 Office furniture, fixtures and equipment 4,718 4,698 Automotive equipment 492 374 Construction in progress 5,591 3,432 136,551 133,241 Less accumulated depreciation (87,576 ) (83,215 ) $ 48,975 $ 50,026

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jun. 30, 2015
Components of Inventories	The components of inventories consist of the following: June 30, December 31, Finished products $ 140,142 $ 142,853 Raw materials 25,092 22,778 $ 165,234 $ 165,631

Segment Reporting (Tables)

Segment Reporting (Tables)	6 Months Ended
	Jun. 30, 2015
Summary of Business Sales Segmentation as per Product	Selective enterprise information is as follows: Three Months Ended Six Months Ended 2015 2014 2015 2014 Net sales: Insecticides $ 27,586 $ 34,524 $ 61,945 $ 80,961 Herbicides/soil fumigants/fungicides 17,451 13,926 39,291 36,857 Other, including plant growth regulators 12,755 8,929 16,077 12,736 57,792 57,379 117,313 130,554 Non-crop 8,731 10,934 15,775 18,854 $ 66,523 $ 68,313 $ 133,088 $ 149,408
Summary of Business Sales Segmentation as per Location	Three Months Ended Six Months Ended 2015 2014 2015 2014 Net sales: US $ 43,842 $ 50,094 $ 93,064 $ 108,050 International 22,681 18,219 40,024 41,358 $ 66,523 $ 68,313 $ 133,088 $ 149,408

Cash Dividends (Tables)

Cash Dividends (Tables)	6 Months Ended
	Jun. 30, 2015
Cash Dividends	The Company declared the following cash dividends in the period covered by this Form 10-Q: Declaration Date Distribution Date Record Date Dividend Per Share Total Paid March 16, 2015 April 17, 2015 April 3, 2015 $0.02 $572

Earnings Per Share (Tables)

Earnings Per Share (Tables)	6 Months Ended
	Jun. 30, 2015
Components of Basic and Diluted Earnings Per Share	The components of basic and diluted earnings per share were as follows: Three Months Ended Six Months Ended 2015 2014 2015 2014 Numerator: Net income attributable to AVD $ 781 $ 145 $ 832 $ 2,304 Denominator: Weighted averages shares outstanding-basic 28,676 28,408 28,602 28,404 Dilutive effect of stock options and grants 526 387 501 473 29,202 28,795 29,103 28,877

Indebtedness (Tables)

Indebtedness (Tables)	6 Months Ended
	Jun. 30, 2015
Summary of Short-Term and Long-Term Loan Balances in Condensed Consolidated Balance Sheets	The Company has a revolving line of credit and various notes payable that together constitute the short-term and long-term loan balances shown in the condensed consolidated balance sheets at June 30, 2015 and December 31, 2014. These are summarized in the following table: Indebtedness June 30, 2015 December 31, 2014 $000’s Long- Short- Total Long- Short- Total Revolving line of credit $ 88,400 $ — $ 88,400 $ 99,400 $ — $ 99,400 Deferred loan fees (804 ) — (804 ) (850 ) — (850 ) Notes payable 18 10,072 10,090 55 71 126 Total indebtedness $ 87,614 $ 10,072 $ 97,686 $ 98,605 $ 71 $ 98,676
Summary of Effect of Derivative Instruments on Statements of Operations and Comprehensive Income	The following tables illustrate the impact of derivatives on the Company’s statements of operations and comprehensive income for the three months and six months ended June 30, 2015 and 2014. The Effect of Derivative Instruments on the Statement of Financial Performance For the three months ended June 30, 2015 and 2014 Amount of Gain or Location of Gain or Amount of Gain or (Loss) Location of Gain or Amount of Gain or Derivatives in ASC 815 Cash Flow Hedging Relationships 2015 2014 OCI into Income 2015 2014 Income on Derivative 2015 2014 Interest rate contracts $ — $ (8 ) Interest Expense $ — $ (153 ) Interest Expense $ — $ — Total $ — $ (8 ) $ — $ (153 ) $ — $ — For the six months ended June 30, 2015 and 2014 Amount of Gain or Location of Gain or Amount of Gain or (Loss) Location of Gain or Amount of Gain or Derivatives in ASC 815 Cash Flow Hedging Relationships 2015 2014 OCI into Income 2015 2014 Income on Derivative 2015 2014 Interest rate contracts $ — $ (31 ) Interest Expense $ — $ (312 ) Interest Expense $ — $ — Total $ — $ (31 ) $ — $ (312 ) $ — $ —

Stock Based Compensation (Table

Stock Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2015
Stock Based Compensation, Unamortized Stock-Based Compensation and Remaining Weighted Average Period	The below tables illustrate the Company’s stock based compensation, unamortized stock-based compensation, and remaining weighted average period for the three months and six months ended June 30, 2015 and 2014. Stock-Based Stock-Based Unamortized Remaining June 30, 2015 Incentive Stock Options $ 116 $ 231 $ 1,204 2.5 Restricted Stock 790 1,962 3,521 1.5 Performance Based Restricted Stock 107 205 811 2.0 Performance Based Options 45 87 454 2.5 Total $ 1,058 $ 2,485 $ 5,990 June 30, 2014 Incentive Stock Options $ 10 $ 21 $ — — Restricted Stock 985 1,819 7,153 2.1 Performance Based Restricted Stock 43 (34 ) 1,559 2.6 Total $ 1,038 $ 1,806 $ 8,712
Summary of Option Activity	Option activity within each plan is as follows: Incentive Weighted Average Exercisable Balance outstanding, December 31, 2014 724,904 $ 9.22 $ 7.82 Options exercised, $7.50 (16,650 ) 7.50 Options forfeited, $11.49 and $13.24 (10,400 ) 11.49 Balance outstanding, March 31, 2015 697,854 $ 9.21 $ 7.71 Options exercised, $7.50 (34,800 ) 7.50 Options forfeited, $11.49 (2,481 ) 11.49 Balance outstanding, June 30, 2015 660,573 $ 9.29 $ 7.72
Summary of Stock Options Summarized by Exercise Price	Information relating to stock options at June 30, 2015 summarized by exercise price is as follows: Outstanding Weighted Average Exercisable Weighted Exercise Price Per Share Shares Remaining Exercise Shares Exercise Incentive Stock Option Plan: $7.50 369,750 64 $ 7.50 369,750 $ 7.50 $11.32—$14.75 290,823 111 $ 11.56 16,679 $ 12.69 660,573 $ 9.29 386,429 $ 7.72
Weighted Average Exercise Prices for Options Granted and Exercisable and Weighted Average Remaining Contractual Life for Options Outstanding	The weighted average exercise prices for options granted and exercisable and the weighted average remaining contractual life for options outstanding as of June 30, 2015 was as follows: Number Weighted Weighted Intrinsic As of June 30, 2015: Incentive Stock Option Plans: Outstanding 660,573 $ 9.29 85 $ 2,987 Expected to Vest 650,455 $ 9.25 84 $ 2,964 Exercisable 386,429 $ 7.72 64 $ 2,354
Performance Based Options
Summary of Option Activity	Performance option activity is as follows: Incentive Weighted Average Exercisable Balance outstanding, December 31, 2014 107,689 $ 11.49 $ — Balance outstanding, June 30, 2015 107,689 $ 11.49 $ —
Summary of Stock Options Summarized by Exercise Price	Information relating to outstanding stock options at June 30, 2015 summarized by exercise price is as follows: Outstanding Weighted Average Exercisable Weighted Exercise Price Per Share Shares Remaining Exercise Shares Exercise Performance Incentive Stock Option Plan: $11.49 107,689 30 $ 11.49 — $ — 107,689 $ 11.49 — $ —
Weighted Average Exercise Prices for Options Granted and Exercisable and Weighted Average Remaining Contractual Life for Options Outstanding	The weighted average exercise prices for options granted and exercisable and the weighted average remaining contractual life for options outstanding as of June 30, 2015 are as follows: Number Weighted Weighted Intrinsic As of June 30, 2015: Incentive Stock Option Plans: Outstanding 107,689 $ 11.49 30 $ 199 Expected to Vest 107,689 $ 11.49 30 $ 199 Exercisable — $ — — $ —
Restricted Stock
Summary of Non-Vested Shares	Restricted Shares — Number Weighted Nonvested shares at December 31, 2014 560,842 $ 21.44 Granted 30,000 11.42 Vested (192,266 ) 20.47 Forfeited (422 ) 14.92 Nonvested shares at March 31, 2015 398,154 $ 21.17 Granted 21,005 14.28 Vested (28,505 ) 13.53 Forfeited (1,201 ) 14.92 Nonvested shares at June 30, 2015 389,453 $ 21.37
Performance Based Restricted Stock
Summary of Non-Vested Shares	Performance Based Shares — Number Weighted Nonvested shares at December 31, 2014 103,907 $ 17.81 Granted 7,500 10.96 Vested — — Forfeited — — Nonvested shares at March 31, 2015 111,407 $ 17.35 Granted — — Vested — — Forfeited — — Nonvested shares at June 30, 2015 111,407 $ 17.35

Accumulated Other Comprehensi33

Accumulated Other Comprehensive Income ("AOCI") (Tables)	6 Months Ended
	Jun. 30, 2015
Beginning Balance, Annual Activity and Ending Balance of Accumulated Other Comprehensive Loss of of Foreign Currency Translation Adjustments	The following table lists the beginning balance, annual activity and ending balance of accumulated other comprehensive loss, which consists of foreign currency translation adjustments: Balance, December 31, 2014 $ (1,970 ) Other comprehensive loss (248 ) Balance, March 31, 2015 $ (2,218 ) Other comprehensive loss (323 ) Balance, June 30, 2015 $ (2,541 )

Summary of Property, Plant and

Summary of Property, Plant and Equipment (Detail) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Property, plant and equipment, Gross	$ 136,551	$ 133,241
Less accumulated depreciation	(87,576)	(83,215)
Total Property, plant and equipment	48,975	50,026
Land
Property, Plant and Equipment [Line Items]
Property, plant and equipment, Gross	2,458	2,458
Buildings and improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, Gross	14,388	14,380
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, Gross	108,904	107,899
Office furniture, fixtures and equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, Gross	4,718	4,698
Automotive equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, Gross	492	374
Construction in progress
Property, Plant and Equipment [Line Items]
Property, plant and equipment, Gross	$ 5,591	$ 3,432

Property, Plant and Equipment -

Property, Plant and Equipment - Additional Information (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2015USD ($)
Property, Plant and Equipment [Line Items]
Elimination of Assets and Accumulated depreciation	$ 231

Components of Inventories (Deta

Components of Inventories (Detail) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Inventory [Line Items]
Finished products	$ 140,142	$ 142,853
Raw materials	25,092	22,778
Total Inventories	$ 165,234	$ 165,631

Segment Reporting - Additional

Segment Reporting - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2015Segment
Number of reportable business segments	1

Summary of Business Sales Segme

Summary of Business Sales Segmentation as per Product (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Net Sales:
Total crop	$ 57,792	$ 57,379	$ 117,313	$ 130,554
Non-crop	8,731	10,934	15,775	18,854
Net sales	66,523	68,313	133,088	149,408
Insecticides
Net Sales:
Total crop	27,586	34,524	61,945	80,961
Herbicides/Soil Fumigants/Fungicides
Net Sales:
Total crop	17,451	13,926	39,291	36,857
Other, Including Plant Growth Regulators
Net Sales:
Total crop	$ 12,755	$ 8,929	$ 16,077	$ 12,736

Summary of Business Sales Seg39

Summary of Business Sales Segmentation as per Location (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Net Sales:
Net sales	$ 66,523	$ 68,313	$ 133,088	$ 149,408
US
Net Sales:
Net sales	43,842	50,094	93,064	108,050
International
Net Sales:
Net sales	$ 22,681	$ 18,219	$ 40,024	$ 41,358

Cash Dividends (Detail)

Cash Dividends (Detail) - Jun. 30, 2015 - USD ($) $ / shares in Units, $ in Thousands	Total
Dividends [Line Items]
Cash dividend declaration date	Mar. 16, 2015
Cash dividend distributed date	Apr. 17, 2015
Cash dividend record date	Apr. 3, 2015
Cash dividend per share	$ 0.02
Cash dividends paid	$ 572

Components of Basic and Diluted

Components of Basic and Diluted Earnings Per Share (Detail) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Numerator:
Net income attributable to AVD	$ 781	$ 145	$ 832	$ 2,304
Denominator:
Weighted averages shares outstanding-basic	28,676	28,408	28,602	28,404
Dilutive effect of stock options and grants	526	387	501	473
Weighted average shares outstanding-assuming dilution	29,202	28,795	29,103	28,877

Earnings Per Share - Additional

Earnings Per Share - Additional Information (Detail) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Components Of Basic And Diluted Earning Per Share [Line Items]
Anti-dilutive stock options excluded from computation of diluted earning per share	0	2,385	0	4,591

Summary Revolving Line of Credi

Summary Revolving Line of Credit And Various Notes Payable Constitute Short-Term and Long-Term Loan Balances Together (Detail) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Extinguishment of Debt [Line Items]
Indebtedness, Long-term	$ 87,614	$ 98,605
Indebtedness, Short-term	10,072	71
Total indebtedness	97,686	98,676
Revolving Line of Credit
Extinguishment of Debt [Line Items]
Indebtedness, Long-term	88,400	99,400
Total indebtedness	88,400	99,400
Deferred Loan Fees
Extinguishment of Debt [Line Items]
Indebtedness, Long-term	(804)	(850)
Total indebtedness	(804)	(850)
Notes payable
Extinguishment of Debt [Line Items]
Indebtedness, Long-term	18	55
Indebtedness, Short-term	10,072	71
Total indebtedness	$ 10,090	$ 126

Indebtedness - Additional Infor

Indebtedness - Additional Information (Detail) - USD ($)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Debt Instrument [Line Items]
Available borrowings capacity under credit agreement		$ 64,057,000
Senior secured credit facility term	5 years
Duration of losses in other comprehensive income expected to be reclassified to earnings	12 months
Maximum
Debt Instrument [Line Items]
Capacity to increase borrowings under credit agreement	$ 27,101,000
Term Loan | Maximum
Debt Instrument [Line Items]
Accordion feature	100,000,000
Revolving Line of Credit
Debt Instrument [Line Items]
Available borrowings capacity under credit agreement	200,000,000
Cash Flow Hedging | Interest Rate Swap
Debt Instrument [Line Items]
Gains (losses) in other comprehensive income expected to be reclassified to earnings	$ 0

Summary of Effect of Derivative

Summary of Effect of Derivative Instruments on Statements of Operations and Comprehensive Income (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain or (Loss) Recognized in OCI on Derivative (Effective Portion)		$ (8)		$ (31)
Amount of Gain or (Loss) Reclassified from Accumulated OCI into Income (Effective Portion)		(153)		(312)
Amount of Gain or (Loss) Recognized in Income on Derivative (Ineffective Portion)	$ 0	0	$ 0	0
Designated as Hedging | Cash Flow Hedging | Interest Rate Contracts
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain or (Loss) Recognized in OCI on Derivative (Effective Portion)		(8)		(31)
Designated as Hedging | Cash Flow Hedging | Interest Rate Contracts | Interest Expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain or (Loss) Reclassified from Accumulated OCI into Income (Effective Portion)		(153)		(312)
Amount of Gain or (Loss) Recognized in Income on Derivative (Ineffective Portion)	$ 0	$ 0	$ 0	$ 0

Stock Based Compensation, Unamo

Stock Based Compensation, Unamortized Stock-Based Compensation and Remaining Weighted Average Period (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	$ 1,058	$ 1,038	$ 2,485	$ 1,806
Unamortized Stock-Based Compensation	5,990	8,712	5,990	8,712
Performance Based Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	45		87
Unamortized Stock-Based Compensation	454		$ 454
Remaining Weighted Average Period (years)			2 years 6 months
Incentive Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	116	10	$ 231	21
Unamortized Stock-Based Compensation	1,204		$ 1,204
Remaining Weighted Average Period (years)			2 years 6 months
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	790	985	$ 1,962	1,819
Unamortized Stock-Based Compensation	3,521	7,153	$ 3,521	$ 7,153
Remaining Weighted Average Period (years)			1 year 6 months	2 years 1 month 6 days
Performance Based Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	107	43	$ 205	$ (34)
Unamortized Stock-Based Compensation	$ 811	$ 1,559	$ 811	$ 1,559
Remaining Weighted Average Period (years)			2 years	2 years 7 months 6 days

Stock Based Compensation Expens

Stock Based Compensation Expense - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended			6 Months Ended		12 Months Ended
	Jun. 30, 2015	Mar. 31, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employees options granted				0
Stock-based compensation	$ 1,058		$ 1,038	$ 2,485	$ 1,806
Common Stock Issued	31,617,282			31,617,282		31,550,477
Incentive Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	$ 116		10	$ 231	21
Nonvested unamortized stock-based compensation, value	1,204			$ 1,204
Nonvested unamortized stock-based compensation, contractual term				2 years 6 months
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	$ 790		985	$ 1,962	$ 1,819
Nonvested unamortized stock-based compensation, contractual term				1 year 6 months	2 years 1 month 6 days
Number of Shares, Granted	21,005	30,000		51,005	240,724
Number of Shares, Vested	28,505	192,266			23,478
Number of years of service before cliff vesting				3 years	3 years
Weighted Average Grant-Date Fair Value, Granted	$ 14.28	$ 11.42		$ 12.60	$ 14.81
Nonvested unamortized stock-based compensation other than options, value	$ 3,521		7,153	$ 3,521	$ 7,153
Restricted Stock | Vested immediately
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Vested				21,005
Restricted Stock | Vest after 90 days
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Vested				7,500
Performance Based Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	$ 107		43	$ 205	$ (34)
Nonvested unamortized stock-based compensation, contractual term				2 years	2 years 7 months 6 days
Number of Shares, Granted		7,500		7,500		0
Number of Shares, Vested	0	0
Weighted Average Grant-Date Fair Value, Granted		$ 10.96
Nonvested unamortized stock-based compensation other than options, value	$ 811		$ 1,559	$ 811	$ 1,559
Cliff vesting date				Jan. 5, 2018
Targeted performance percentage	200.00%			200.00%
Performance Based Restricted Stock | Performance Based Shares Based Upon Financial Performance of Earnings before Interest Tax ("EBIT") and Net Sales Goal for the Period Commencing January 1, 2015 and Ending December 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of shares vesting based on Performance				80.00%
Earnings before income tax goal weight, percentage				50.00%
Net sales goal weight, percentage				30.00%
Performance Based Restricted Stock | Performance Based Shares Based Upon AVD Stock Price Appreciation Over the Course of the Period Commencing January 1, 2015, Ending December 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of shares vesting based on Performance				20.00%
Performance Based Restricted Stock | Performance Based Shares Related to Net Income Weighted at 50%, Net Sales Weighted at 30%, Commencing January 1, 2015 and Ending December 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Grant-Date Fair Value, Granted				$ 11.42
Performance Based Restricted Stock | Remaining 20% of Performance Based Shares are Based Upon AVD Stock Price Appreciation for the Period Commencing January 1, 2015 and Ending December 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Grant-Date Fair Value, Granted				$ 9.13
Performance Based Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	$ 45			$ 87
Nonvested unamortized stock-based compensation, value	$ 454			$ 454
Nonvested unamortized stock-based compensation, contractual term				2 years 6 months
Common Stock Issued						0

Summary of Option Activity (Det

Summary of Option Activity (Detail) - $ / shares	3 Months Ended
	Jun. 30, 2015	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incentive Stock Option Plans, Beginning balance	697,854	724,904
Incentive Stock Option Plans, Option exercised	(34,800)	(16,650)
Incentive Stock Option Plans, Option forfeited	(2,481)	(10,400)
Incentive Stock Option Plans, Ending balance	660,573	697,854
Weighted Average Price Per Share, Beginning balance	$ 9.21	$ 9.22
Weighted Average Price Per Share, Option exercised	7.50	7.50
Weighted Average Price Per Share, Option forfeited	11.49	11.49
Weighted Average Price Per Share, Ending balance	9.29	9.21
Exercisable Weighted Average Price Per Share, Beginning balance	7.71	7.82
Exercisable Weighted Average Price Per Share, Ending balance	$ 7.72	$ 7.71
Performance Based Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incentive Stock Option Plans, Beginning balance		107,689
Incentive Stock Option Plans, Ending balance	107,689
Weighted Average Price Per Share, Beginning balance		$ 11.49
Weighted Average Price Per Share, Ending balance	$ 11.49

Summary of Option Activity (Par

Summary of Option Activity (Parenthetical) (Detail) - $ / shares	3 Months Ended
	Jun. 30, 2015	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Price Per Share, Option exercised	$ 7.50	$ 7.50
Weighted Average Price Per Share, Option forfeited	$ 11.49	11.49
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Price Per Share, Option forfeited		11.49
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Price Per Share, Option forfeited		$ 13.24

Summary of Stock Options Summar

Summary of Stock Options Summarized by Exercise Price (Detail) - $ / shares	6 Months Ended
	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Weighted Average, Exercise Price	$ 9.29	$ 9.21	$ 9.22
Exercisable Weighted Average, Exercise Price	$ 7.72	$ 7.71	7.82
Incentive Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Weighted Average, Shares	660,573
Outstanding Weighted Average, Remaining Life (Months)	85 months
Outstanding Weighted Average, Exercise Price	$ 9.29
Exercisable Weighted Average, Shares	386,429
Exercisable Weighted Average, Exercise Price	$ 7.72
Incentive Stock Option Plan | Range One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Per Share, Lower Range	$ 7.50
Outstanding Weighted Average, Shares	369,750
Outstanding Weighted Average, Remaining Life (Months)	64 months
Outstanding Weighted Average, Exercise Price	$ 7.50
Exercisable Weighted Average, Shares	369,750
Exercisable Weighted Average, Exercise Price	$ 7.50
Incentive Stock Option Plan | Range Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Per Share, Lower Range	11.32
Exercise Price Per Share, Upper Range	$ 14.75
Outstanding Weighted Average, Shares	290,823
Outstanding Weighted Average, Remaining Life (Months)	111 months
Outstanding Weighted Average, Exercise Price	$ 11.56
Exercisable Weighted Average, Shares	16,679
Exercisable Weighted Average, Exercise Price	$ 12.69
Performance Based Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Weighted Average, Shares	107,689
Outstanding Weighted Average, Remaining Life (Months)	30 months
Outstanding Weighted Average, Exercise Price	$ 11.49		$ 11.49
Performance Based Options | Range Three
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Per Share, Lower Range	$ 11.49
Outstanding Weighted Average, Shares	107,689
Outstanding Weighted Average, Remaining Life (Months)	30 months
Outstanding Weighted Average, Exercise Price	$ 11.49

Weighted Average Exercise Price

Weighted Average Exercise Prices for Options Granted and Exercisable and Weighted Average Remaining Contractual Life for Options Outstanding (Detail) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding	660,573	697,854	724,904
Weighted Average Exercise Price, Outstanding	$ 9.29	$ 9.21	$ 9.22
Weighted Average Exercisable, Exercise Price	$ 7.72	$ 7.71	$ 7.82
Incentive Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding	660,573
Number of Shares, Expected to Vest	650,455
Number of Shares, Exercisable	386,429
Weighted Average Exercise Price, Outstanding	$ 9.29
Weighted Average Exercise Price, Expected to Vest	9.25
Weighted Average Exercisable, Exercise Price	$ 7.72
Weighted Average Remaining Life, Outstanding	85 months
Weighted Average Remaining Contractual Life, Expected to Vest	84 months
Weighted Average Remaining Contractual Life, Exercisable	64 months
Intrinsic Value, Outstanding	$ 2,987
Intrinsic Value, Expected to Vest	2,964
Intrinsic Value, Exercisable	$ 2,354
Performance Based Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding	107,689		107,689
Number of Shares, Expected to Vest	107,689
Weighted Average Exercise Price, Outstanding	$ 11.49		$ 11.49
Weighted Average Exercise Price, Expected to Vest	$ 11.49
Weighted Average Remaining Life, Outstanding	30 months
Weighted Average Remaining Contractual Life, Expected to Vest	30 months
Intrinsic Value, Outstanding	$ 199
Intrinsic Value, Expected to Vest	$ 199

Summary of Non-Vested Shares (D

Summary of Non-Vested Shares (Detail) - Restricted Stock - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Mar. 31, 2015	Jun. 30, 2015	Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Beginning balance	398,154	560,842	560,842
Number of Shares, Granted	21,005	30,000	51,005	240,724
Number of Shares, Vested	(28,505)	(192,266)		(23,478)
Number of Shares, Forfeited	(1,201)	(422)
Number of Shares, Ending Balance	389,453	398,154	389,453
Weighted Average Grant-Date Fair Value, Beginning balance	$ 21.17	$ 21.44	$ 21.44
Weighted Average Grant-Date Fair Value, Granted	14.28	11.42	12.60	$ 14.81
Weighted Average Grant-Date Fair Value, Vested	13.53	20.47
Weighted Average Grant-Date Fair Value, Forfeited	14.92	14.92
Weighted Average Grant-Date Fair Value, Ending balance	$ 21.37	$ 21.17	$ 21.37

Status Summary of Non-Vested Sh

Status Summary of Non-Vested Shares (Detail) - Performance Based Restricted Stock - $ / shares	3 Months Ended		6 Months Ended	12 Months Ended
	Jun. 30, 2015	Mar. 31, 2015	Jun. 30, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Beginning balance	111,407	103,907	103,907
Number of Shares, Granted		7,500	7,500	0
Number of Shares, Vested	0	0
Number of Shares, Forfeited	0	0
Number of Shares, Ending Balance	111,407	111,407	111,407	103,907
Weighted Average Grant-Date Fair Value, Beginning balance	$ 17.35	$ 17.81	$ 17.81
Weighted Average Grant-Date Fair Value, Granted		10.96
Weighted Average Grant-Date Fair Value, Vested	0	0
Weighted Average Grant-Date Fair Value, Forfeited	0	0
Weighted Average Grant-Date Fair Value, Ending balance	$ 17.35	$ 17.35	$ 17.35	$ 17.81

Legal Proceedings - Additional

Legal Proceedings - Additional Information (Detail) $ in Thousands	May. 13, 2015USD ($)	Apr. 14, 2014PlaintiffDefendant	May. 12, 2015USD ($)
USEPA TSCA Matter
Loss Contingencies [Line Items]
Settlement amount	$ 81
Loss contingency	$ 81
Schiemer Farms Matter
Loss Contingencies [Line Items]
Alleged loss of yield			$ 1,200
Sanchez v. Agro Logistic Systems, Inc et al
Loss Contingencies [Line Items]
Number of defendants | Defendant		27
Number of individuals seek unspecified damages | Plaintiff		2

Equity Investment - Additional

Equity Investment - Additional Information (Detail) £ in Thousands, $ in Thousands	Mar. 25, 2013USD ($)	Feb. 28, 2014USD ($)shares	Feb. 28, 2014GBP (£)shares	Jun. 30, 2015USD ($)	Jun. 30, 2014USD ($)
Equity Method Investments [Line Items]
Equity investment	$ 3,687
Gain on dilution of equity method investment					$ 256
Equity investment ownership position	29.27%			21.18%
Loss from equity method investment				$ (191)	$ (396)
Carrying value of equity investment				2,981
Quoted market value of equity investment				$ 4,148
TyraTech Inc.
Equity Method Investments [Line Items]
Shares issued by equity investee | shares		37,391,763	37,391,763
Amount raised by equity investee on shares issued		$ 3,100	£ 1,870

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Income Taxes [Line Items]
Income taxes (benefit) expense	$ (393)	$ (160)	$ (685)	$ 856
Effective tax rate			(339.10%)	27.00%